Neuchâtel, Neuchâtel, Switzerland
Strategic biopharmaceutical leader with 18+ years’ experience in global program and portfolio management and leadership roles, across multiple therapeutic areas and modalities with strong emphasis in hematology and oncology. Proven ability to lead cross-functional teams, drive asset strategy, and deliver complex programs from discovery through late-stage development. Expert in portfolio optimization, risk management, and talent development. Recognized for building high-performing teams, accelerating development timelines, and maximizing asset value in dynamic, matrixed environments. Specialities/Previous experience: - Project Management - Portfolio Management - Portfolio Performance Evaluation and Prioritization - Direct and and Matrix Cross Functional Team Leadership - Partnering and Alliance Management - Resource, budget, risk, stakeholder management and processes set up - Personalized Medicine, diagnostic and patient stratification biomarkers in clinical setting - Small molecules and Biologics - Early and Late drug development, Life Cycle Management, Branded Generics - Therapeutic areas: Hematology, Oncology, Cardio, Metabolic, Respiratory, Immunology, Gastroenterology - Lean Six Sigma Methodology and tools
• Lead and develop the late development Hematology Project Management group, providing line management, coaching, and career advancement for Project Managers. • Member of the DD PM Leadership Team, partnering to define the vision and roadmap for PM as part of the overall Portfolio Program Management (PPM) group and building a strong PM organization and talent pipeline to support the evolving needs of the organization. • Project Management Lead for the Golcadomide program, advancing asset strategy and ensuring execution of approved studies and life cycle management plans. • Champion innovative approaches to accelerate program development. • Oversee integrated project planning, budget /timelines scenario generation, and risk assessment for global programs, supporting robust governance and portfolio optimization. • Drive operational excellence and strategic execution across multiple indications and geographies, including global collaborations and new opportunity assessments in lymphoma. • Provide confident, positive, and persistent Project Management leadership through organizational changes, maintaining team alignment and stakeholder engagement.
• Late development Hematology Project Manager for Golcadomide and Iber Lymphoma programs. Strategic partner of the GPL, leading as a COO and driving operational execution toward key milestones. • Managed program strategy and implementation in multiple indications, including global development paths for China and Japan, and supported external clinical collaborations. • Supported as Project Manager Lymphoma Disease Strategy Team • Project Management lead for Quantum Leap Protocol Fast Track project for first Ph3 high-priority study. • Drove the team with confidence, positivity, persistence, and dedication through multiple changes within the program and the Governance Organization, aiming to ensure alignment within the team and with stakeholders towards asset targets and milestones.
• Led Program Leadership and Project Management organization, overseeing strategic and operational direction for portfolio assets in hematology, oncology, endocrinology, and infectious diseases. • Managed departmental headcount, talent acquisition, hiring, coaching, and career development for direct reports. • Acted as Global Program Head for IAP inhibitors programs in Oncology, leading cross-functional teams and driving development up to Ph3 start and successful out-license. • Supported License in and license out opportunities’ evaluation in multiple therapeutic areas.
• Managed cross functional Immuno-Oncology, haematology and solid tumours project teams in late stage drug development, and led early stage combination opportunities on dedicated programs. • Drove program strategy, assessing new development opportunities for business growth in new indications or combination therapies. • Accountable for development and maintenance of integrated project plan, program budget scenarios planning generation and risk assessment. • Alliance management of strategic collaborations and co-development partners. • Managed license in opportunities evaluation for combination therapies within the program and new compounds within the therapeutic area. • Contributed to project management initiatives on processes optimizations such as project risk assessment, portfolio reporting activities, Life Cycle Strategic Plan and TPP harmonization process.
• Managed cross functional project teams in early development stage. Contributed on identification and development of project strategy and ensured strategy implementation by the project teams and functions. • Risk management – ensured anticipation, identification, management and communication of project risks. • Enabled generation of innovative, exploratory and/or confirmatory development options. Responsible for consistent project planning from exploratory through full development. Accountable for development and maintenance of integrated project plan budget and resources. • Guided due diligence teams on assessing potential license in opportunities. Formation of comprehensive drug development plan and budget.
• Developed and maintained integrated Brand commercial and development strategies generating and implementing innovation projects. Led cross functional global brand teams of products in hypertension, thyroid and gastrointestinal disorders and ensured strong collaboration with the affiliates. • Fostered innovation and identified growth opportunities in new markets, alternative formulations and new indications. Generated and maintained global Brand plan including budget and resources and risk management plan. • Member of the Project & Portfolio management team, contributed to the portfolio expansion and prioritization process from acquired portfolios. • Member of the Abbott Established Pharmaceuticals and Diagnostics Cross Divisional Initiative aiming to identify synergies and collaboration opportunities between divisions.